ACHV

Achieve Life Sciences, Inc. (ACHV) - 10-K Summary

Business Context and Reporting Period

Company: Achieve Life Sciences, Inc.
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline, a naturally occurring alkaloid for smoking and e-cigarette (vaping) cessation.
Key Milestone: In September 2025, the FDA accepted for review the New Drug Application (NDA) for cytisinicline for smoking cessation, assigning a PDUFA target action date of June 20, 2026. The company also received Breakthrough Therapy designation and a Commissioner's National Priority Voucher (CNPV) for the vaping cessation indication.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The company has no revenue from product sales. Expenses increased primarily due to commercial launch preparation costs ($12.3 million in 2025 vs $1.2 million in 2024) and higher stock-based compensation.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss widened by approximately $14.8 million year-over-year, driven by a $15.6 million increase in General and Administrative expenses related to commercialization readiness.
• Debt Financing: The company drew down a second tranche of $5.0 million on its New Convertible Term Loan in October 2025, bringing total principal to $15.0 million. The third tranche expired unused on December 31, 2025.
• Capital Raising: Completed a public offering in June 2025, raising approximately $45.2 million in gross proceeds (net of ~$4.1 million in expenses).
• Cash Flow: Net cash used in operating activities increased to $49.5 million in 2025 from $29.8 million in 2024, largely due to the ORCA-OL open-label safety trial costs.

Guidance, Outlook, Risks, and Contingencies

Outlook & Guidance:

• Commercial Launch: Anticipated for the first half of 2027, pending FDA approval.
• Regulatory: FDA PDUFA date for smoking cessation is June 20, 2026. Potential delays exist due to FDA observations at a third-party manufacturer named in the NDA.
• Liquidity: Management states current resources are insufficient to fund planned operations for the next 12 months. Substantial additional capital is required.

Material Risks & Contingencies:

• Going Concern: The auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
• Manufacturing Dispute: A dispute exists with primary supplier Sopharma regarding the engagement of third-party manufacturers (Adare Pharma Solutions) to mitigate supply chain risks. Sopharma alleges this is a breach of contract.
• Regulatory Approval: No guarantee of FDA approval. If approval is delayed or denied, the company may be unable to generate revenue.
• Debt Covenants: The company is restricted from paying dividends and must maintain cash balances at Silicon Valley Bank (SVB). Failure to service debt could lead to foreclosure on assets.

Investor Verification Checklist

• Capital Runway: Verify the timeline and terms of any new financing required to bridge the gap to commercial launch, given the "substantial doubt" going concern warning.
• Manufacturing Resolution: Monitor the status of the dispute with Sopharma and the progress of technology transfer with Adare Pharma Solutions to ensure supply chain redundancy.
• FDA Inspection Status: Track the resolution of the FDA observations at the third-party manufacturer named in the NDA, as this poses a risk to the June 2026 PDUFA date.
• Commercialization Costs: Assess the sustainability of the increased G&A spend ($31.9M) as the company transitions from clinical to commercial operations without revenue.
• Dilution Risk: Review the terms of the convertible debt (conversion prices of $7.00 and ~$4.85) and outstanding warrants (20.5 million shares) for potential dilution upon conversion or exercise.